Neurogene (NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a phase 1/2 trial for NGN-401, its gene therapy candidate targeting Rett syndrome.
The study included pediatric patients given low and high dosages of NGN-401. All four of the low-dose group members exhibited improvement, scoring 2 on the Clinical Global Impression Scale of Improvement, thereby indicating significant change from baseline. The business also reports that these individuals showed a 28% to 52% improvement on the Rett Syndrome Behavior Questionnaire.
Nonetheless, consistent with recognized dangers of AAV (adeno-associated virus) gene treatments, one of the two patients in the high-dose group had a major adverse event connected to the therapy, as reported in a corporate statement.
In order to evaluate the effectiveness of NGN-401 across a larger population, Neurogene also started a new cohort within the study including teenage and adult participants aged 16 and above. Three people are likely to be part of the high-dose group in this new cohort.
In a separate update, Neurogene said its only other clinical-stage asset, NGN-101 gene therapy candidate for CLN5 Batten disease, would not be further developed.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.